Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial

Fig. 3

Changes in HbA1c, FBS, GLP-1 and body weight between baseline and 24 weeks later. The decreases in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group. GLP-1 level increased from baseline to 24 weeks later in the sitagliptin group but not in the voglibose group. FBS, fasting blood sugar; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; W, weeks

Back to article page